IDXX — IDEXX LABORATORIES INC /DE
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 874716 ·
Last close
$570.58
Market Cap
$45.01B
52W High
$624.15
52W Low
$518.55
ADV30
647,725
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 1,140,820,000 | 722,739,000 | 362,586,000 | 278,446,000 | 3,385,497,000 | 200,528,000 | 1,829,394,000 |
| Dec 2025 | 1,090,579,000 | 658,114,000 | 315,605,000 | 248,188,000 | 3,350,759,000 | 180,070,000 | 1,745,376,000 |
| Sep 2025 | 1,105,239,000 | 683,354,000 | 354,846,000 | 274,610,000 | 3,386,712,000 | 208,166,000 | 1,825,526,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,210,091,000
Investing CF
$-140,173,000
Financing CF
$-1,046,073,000
CapEx
$-141,984,000
Dividends Paid
—
Buybacks
$-1,167,110,000
EPS Diluted TTM
$14.22
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$6,670,348,000
Inventory
$382,400,000
Receivables
$697,212,000
ST Investments
—
EBIT TTM
$1,408,474,000
Pretax Income TTM
$1,369,547,000
Interest Exp TTM
$38,927,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,553,223,168
EBITDA
$1,621,684,992
Free Cash Flow
$909,368,384
Enterprise Value
$45,850,075,136
Total Cash
$196,932,992
Total Debt
$1,096,081,024
Shares Out
78,882,997
Trailing EPS
$13.87
Book Value
$20.45
ROE
74.2%
ROA
27.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,303,702,000 | 1,360,031,000 | 1,059,464,000 | 3,350,759,000 | 1,745,376,000 | — | 1,181,805,000 |
| Dec 2024 | 3,897,504,000 | 1,128,337,000 | 887,867,000 | 3,293,443,000 | 1,698,130,000 | — | 929,001,000 |
| Dec 2023 | 3,660,953,000 | 1,097,128,000 | 845,042,000 | 3,259,925,000 | 1,775,395,000 | — | 906,510,000 |
| Dec 2022 | 3,367,324,000 | 898,765,000 | 679,089,000 | 2,746,765,000 | 2,138,028,000 | — | 542,984,000 |
TTM Snapshot
Revenues TTM
$3,543,152,000
NetIncome TTM
$801,245,000
OpCashFlow TTM
$0
Assets (Latest)
$3,293,443,000
Forward EPS
$16.74
Max Pain — expiry 2026-08-21
max pain strike: $560.00 · spot: $566.93 · call oi: 1,318 · put oi: 1,081
Expected Move to 2026-08-21:
±$22.05
(3.89%) —
implied range
$544.88 –
$588.98
· ATM straddle on $570.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $39.79B | $241.71 | — |
| INCY | INCYTE CORP | $24.48B | $120.77 | — |
| MEDP | Medpace Holdings, Inc. | $16.66B | $596.98 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $13.58B | $284.37 | — |
| ICLR | ICON PLC | $12.90B | $167.17 | — |
News headlines (Yahoo Finance, 1h cache)
Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?
2026-08-13 02:10 · Yahoo
IDEXX (IDXX) Q2 2026 Earnings Call Transcript
2026-08-11 16:28 · Yahoo
Here is Why Growth Investors Should Buy Idexx (IDXX) Now
2026-08-06 16:45 · Yahoo
IDEXX Laboratories Q2 Earnings Call Highlights
2026-08-04 16:04 · Yahoo
Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say
2026-08-04 13:30 · Yahoo
IDEXX Laboratories Shares Climb After Earnings Beat and Improved Full-Year Outlook
2026-08-04 12:15 · Yahoo
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
2026-08-11 11:00 · Yahoo
IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary
2026-08-04 22:15 · Yahoo
IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ...
2026-08-04 21:04 · Yahoo
IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market
2026-08-04 15:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.